February 22, 2018 / 5:37 PM / 8 months ago

BRIEF-Geneuro Receives Orphan Drug Designation From The Us FDA For Gnbac1 In Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Geneuro Sa:

* GENEURO RECEIVES ORPHAN DRUG DESIGNATION FROM THE US FDA FOR GNBAC1 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)

* FORTHCOMING DISCUSSIONS EXPECTED WITH FDA FOR DESIGN OF A PROOF-OF-CONCEPT PHASE 2 CLINICAL STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below